Post-earnings recap
Reported
Wed, May 6, 2026
EPS actual
$0.19
EPS est.
—
EPS surprise
—
1-day move
-1.66%
ADMA Biologics reported earnings that fell short of revenue expectations, which may have contributed to the stock's decline of 1.66%. The company did not provide any forward guidance or additional commentary, leaving investors without insights into future performance. The missed revenue target could raise concerns about sales growth and market demand for their products.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.19 | $0.20 | — |
| Revenue | — | $140M | — |
No transcript is on record for this earnings call, and the analysis is based solely on numerical results.
ADMA Biologics, Inc. is a biotechnology company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies and infectious diseases. Operating in the Health Care sector, ADMA is significant for its contributions to the growing field of immunotherapy and the production of high-quality immunoglobulin therapies.
Last quarter
In the last quarter, ADMA reported an EPS of $0.20, meeting expectations. The stock reacted positively, gaining 1.03% the following day.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
+23.07%
Avg 1-day reaction
+0.64%
Analysts expect ADMA to report earnings that meet or slightly exceed the consensus estimates. The market is keenly watching for any signs of growth in revenue and profitability.
Bull case
If ADMA can demonstrate strong revenue growth and maintain or improve its EPS, it could signal robust demand for its products and lead to a positive stock reaction.
Bear case
Conversely, if the company fails to meet revenue expectations or shows signs of declining profitability, it could lead to a significant drop in stock price.
Key metrics to watch
EPS
$0.20Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$140MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will ADMA's revenue exceed the consensus estimate of $140 million?
Revenue growth is crucial for demonstrating market demand and the company's ability to scale its operations.
Q2
Can ADMA maintain its EPS at $0.20 or better?
Earnings per share is a direct measure of profitability, and maintaining or exceeding this figure could boost investor confidence.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate ADMA's ability to leverage recent product developments and market expansion, which could lead to stronger-than-expected revenue growth.
Supporting evidence
The company's recent performance has shown resilience, with a 71% EPS beat rate historically.
Options pricing suggests a significant move, indicating that traders are anticipating volatility, which could reflect underlying strength.
Insider selling activity could indicate confidence in the company's future prospects despite the recent stock performance.
Key risk
If revenue comes in significantly above $140 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it will indicate whether ADMA can sustain its growth trajectory amid market challenges.
Bull confirmed if
Revenue growth above $140 million with EPS at or above $0.20 would confirm the bull case.
Bear confirmed if
Any revenue below $138 million or EPS below $0.20 would support the bear case.
What the market is pricing for the move.
Implied Move
±15.71%
Historical Avg
±2.5%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±18.0% while ADMA has averaged ±2.5% over the last 8 prints — setup is pricing rich.
ATM IV
1.2%
30d HV
96.3%
Smart-money positioning from the most recent 13F filings.
Institutional
92.76%
of float
Insider
1.97%
of float
Holders
437
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
38,355,684 sh · $388.9M
17.12%
4.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If ADMA beats expectations, history suggests a positive stock reaction, averaging a 0.42% increase.
In line / cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.
Miss
A miss could lead to a more significant decline, with history suggesting an average drop of 3.59%.
The lines on the call that would change the story.
State Street Corporation
17,116,022 sh · $173.6M
7.64%
21.5%
Vanguard Capital Management LLC
10,103,809 sh · $102.5M
4.51%
-2.0%
Vanguard Portfolio Management LLC
10,088,490 sh · $102.3M
4.50%
13.8%
Rubric Capital Management LP
9,339,414 sh · $94.7M
4.17%
416.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.